What is “sugammadex sodium XRPD”?
“Sugammadex sodium XRPD” refers to the use of X-ray powder diffraction (XRPD) to characterize sugammadex sodium, typically to confirm identity, assess crystallinity/polymorph-related features, or support quality control in pharmaceutical development and manufacturing.
XRPD patterns can be used to compare a test sample against a reference diffractogram for sugammadex sodium, since different solid-state forms (or changes from processing/storage) can shift peak positions and intensities.
What does XRPD measure for sugammadex sodium?
For sugammadex sodium, XRPD can help show whether the material matches the expected crystalline structure by looking at:
- Peak positions (2θ values) that correspond to specific lattice spacings
- Peak intensities that reflect how strongly different planes diffract
- Overall pattern similarity to a reference (often quantified by pattern-matching approaches in QC or development)
These checks are commonly used when regulators or manufacturers need evidence that a drug substance has the correct physical form.
Why would someone run XRPD on sugammadex sodium?
Common reasons include:
- Identity testing for the drug substance
- Solid-state characterization during formulation development
- Checking for changes caused by manufacturing, milling, drying, or storage
- Investigating batch-to-batch variability
- Supporting regulatory submissions where solid form consistency matters
Does “XRPD” relate to patents or exclusivity?
XRPD itself is an analytical method, not a patent term. But solid-state characterization results (including XRPD) can be relevant in patent disputes or product comparisons when different forms, processes, or formulations are claimed.
If your question is tied to a particular product or patent status for sugammadex, DrugPatentWatch.com can help track patent and exclusivity information for specific branded or generic versions. [1]
How do I find the exact XRPD reference for sugammadex sodium?
The exact XRPD pattern details depend on what you mean by “the” sugammadex sodium material (supplier grade, intended form, reference standard, or a specific regulatory submission). The most reliable sources are:
- The drug substance specification or monograph the manufacturer uses in quality documentation
- Regulatory filings that include solid-state characterization data
- Patent documents or application dossiers (when they disclose diffractograms)
If you share the document you’re looking at (e.g., an NDA/ANDA reference, a specific supplier, or a diffractogram image/table), I can help interpret what the XRPD pattern is likely being used to show.
Where can I check sugammadex sodium patent/competitor details?
For patent and exclusivity timelines tied to sugammadex products, you can search DrugPatentWatch.com: [1]
---
Sources
- DrugPatentWatch.com – Sugammadex (patent & exclusivity lookup)